'RHONJ''s Dolores Catania Says She Gained 20 Lbs. After Mounjaro ‘Stopped Working': ‘I'm Having a Really Hard Time'
Dolores Catania revealed she gained 20 lbs. after her Mounjaro 'stopped working'
The RHONJ star she's 'having a really hard time' dealing with the weight gain
She admitted that there's a possibility her weight gain could be due to the slew of heart medications she's been takingDolores Catania is struggling with weight gain even while taking Mounjaro.
On June 6, the Real Housewives of New Jersey star, 54, appeared on SiriusXM's Jeff Lewis Live and talked about taking Mounjaro, an FDA-approved prescription medication for people with type 2 diabetes. It's a brand name for tirzepatide, which is highly effective for weight loss by reducing appetite and improving how the body breaks down sugar and fat.
Mounjaro is similar to Ozempic and Wegovy — brand names for semaglutide. They work in the brain to impact satiety and have been trending in and out of Hollywood.
Catania — who previously shared that she lost 20 lbs. with the medication — revealed on the show that she's now gained the weight back.
'I'm having a really hard time right now. My Mounjaro stopped working, I gained 20 lbs.,' she shared. 'I've been looking for therapy for all my friends. I'm really having a bad time with this.'
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
Lewis asked if she's able to switch to another medication like Ozempic and she immediately replied, 'I did it all.'
Catania said she has since stopped taking the medication for about a month because she needed to undergo a cardiac ablation — a minimally invasive procedure where doctors freeze or burn the inside of the heart to restore a normal heart rhythm.
The Bravo star assured that she's 'fine' now and was only in the hospital for the procedure.
'I'm on a bunch of medicine, like, 10 pills a day,' she said. 'It's just a formality now. I have to take it for the next 90 days, then I should be done.'
'Maybe that's why I gained weight,' she said of all the new medications. 'I'm hoping maybe that's why.'
!
is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more!
Catania previously spoke about her success on Mounjaro in 2023.
"I'm down 20 pounds," she told The U.S. Sun, adding that her goal weight "is to be in the low 130s."
The reality star admitted that she was previously 'gaining weight every month' and got up to 163 lbs. before trying the medication and seeing some results. 'It doesn't happen overnight. It doesn't come off easy," she said.
Catania was originally prescribed Ozempic, taking the drug for two years before switching to Mounjaro in early 2023.
'I was medically prescribed for both because I am insulin resistant/pre-diabetic and have a thyroid issue,' she said at the time.
Catania stressed that although she was still hoping to lose more weight on Mounjaro, taking these medications isn't a quick fix to weight loss, insisting that she focuses on exercising, healthy eating, and limiting her drinking — minus the wild nights spent with her RHONJ castmates.
"I stopped taking [Ozempic] because it was expensive and everything. But being healthy and living a healthy lifestyle is cheap — it's free!" she told the outlet. "I work out regularly. There is no easy fix for weight loss and I have to watch what I eat."
Read the original article on People
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Penumbra may gain market share in peripheral embolisation coils with Ruby XL
Penumbra has announced US Food and Drug Administration approval for its Ruby XL system, which includes three coils: the Ruby XL, the POD XL and the Packing Coil XL. The Ruby XL coil is a device used in vascular embolisation, a procedure to block or close off blood vessels, and can be used to frame large aneurysms, while the POD XL is designed for use in high-flow vessels and the Packing Coil XL is designed to adjust to the shape of any vessel up to 70cm in length. All Ruby XL system coils can be delivered through a 0.035-inch diagnostic catheter. The system is expected to enable Penumbra to increase its market share in peripheral embolisation coils, according to leading data and analytics company GlobalData. According to GlobalData's US healthcare facility invoicing database, Penumbra currently holds the majority market share for peripheral embolisation coils. Its new coil system allows for peripheral embolisation procedures to be done on a wider range of aneurysm sizes and in longer vessels. If the Ruby XL coil is widely adopted by physicians, Penumbra may be able to capture half the entire market. The approval of the new coil could put a bigger gap between Penumbra and its competitors in the market. Physicians may choose Ruby XL coils for their procedures in order to gain better control of large aneurysms. The Ruby XL system may come with cost savings for consumers as it delivers more volume per coil than other available coils. The average selling price (ASP) of these coils ranges from approximately $900 to $2,000. Already in the middle of this range with its current coils, Penumbra has a competitive advantage for new products. If they come in with a competitive ASP, Penumbra may displace competitor coils for relevant procedures. Penumbra stands to maintain its market lead and possibly increase its market share as the purchasing of the Ruby XL system begins. GlobalData will continue to monitor market trends as purchasing picks up. It is expected that facilities will begin purchasing these coils in June 2025. "Penumbra may gain market share in peripheral embolisation coils with Ruby XL" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
DentalMonitoring Launches "Top Ortho Practice Award" to Recognize Data-Driven Excellence in Orthodontic Care
PARIS--(BUSINESS WIRE)--DentalMonitoring, the global leader in AI-powered remote monitoring for orthodontics, is proud to announce the launch of the Top Ortho Practice Award, the first-of-its-kind recognition program that celebrates top-performing orthodontic practices worldwide through objective, data-based analysis. 'The Top Ortho Practice Award is the first global program to recognize orthodontic excellence based on objective clinical data, not popularity.' Unlike traditional awards based on subjective nominations or popularity, the Top Ortho Practice Award is rooted in objective metrics derived from millions of patient scans and clinical interactions. Practices are selected based on exceptional outcomes in hygiene, compliance, and treatment effectiveness, using standardized benchmarks that reflect regional and global performance levels. The program identifies and celebrates practices that lead their territories in performance metrics derived from actual patient data, including hygiene, clinical techniques, and post-treatment stability. These practices will also serve as mentors and knowledge hubs, openly sharing their techniques, workflows, and philosophies to support peer learning and collective growth. DentalMonitoring will host its first Top Ortho Practice Exchange Event live in Las Vegas on September 18th, 2025, before the OP Summit 2025. Sign up here to register 'This initiative is about more than recognition — it's about raising the bar for what's possible in orthodontic care,' said Philippe Salah, CEO of DentalMonitoring. 'By highlighting data-backed excellence, we're helping the industry move toward more measurable, scalable impact.' Through this initiative, DentalMonitoring reaffirms its commitment to transforming orthodontics, motivating practices to unlock their full potential, and ultimately supporting them in delivering better care to patients everywhere. About DentalMonitoring DentalMonitoring sets new standards in orthodontics with its AI-powered, FDA De Novo-approved, and MDR-certified remote monitoring software. Designed for use with multiple appliances or treatment phases, it enables doctors to monitor patients remotely, enhance clinical control, and improve efficiency. Patients benefit from features like in-app messaging, convenient guided scans, and real-time feedback. With its latest innovations, DentalMonitoring helps practices optimize workflows and deliver outstanding care. With over 13,000 clinical data results, DentalMonitoring is transforming the orthodontic experience for patients and practices worldwide by connecting innovation with orthodontic needs.
Yahoo
2 hours ago
- Yahoo
DentalMonitoring Launches "Top Ortho Practice Award" to Recognize Data-Driven Excellence in Orthodontic Care
PARIS, June 20, 2025--(BUSINESS WIRE)--DentalMonitoring, the global leader in AI-powered remote monitoring for orthodontics, is proud to announce the launch of the Top Ortho Practice Award, the first-of-its-kind recognition program that celebrates top-performing orthodontic practices worldwide through objective, data-based analysis. Unlike traditional awards based on subjective nominations or popularity, the Top Ortho Practice Award is rooted in objective metrics derived from millions of patient scans and clinical interactions. Practices are selected based on exceptional outcomes in hygiene, compliance, and treatment effectiveness, using standardized benchmarks that reflect regional and global performance levels. The program identifies and celebrates practices that lead their territories in performance metrics derived from actual patient data, including hygiene, clinical techniques, and post-treatment stability. These practices will also serve as mentors and knowledge hubs, openly sharing their techniques, workflows, and philosophies to support peer learning and collective growth. DentalMonitoring will host its first Top Ortho Practice Exchange Event live in Las Vegas on September 18th, 2025, before the OP Summit 2025. Sign up here to register "This initiative is about more than recognition — it's about raising the bar for what's possible in orthodontic care," said Philippe Salah, CEO of DentalMonitoring. "By highlighting data-backed excellence, we're helping the industry move toward more measurable, scalable impact." Through this initiative, DentalMonitoring reaffirms its commitment to transforming orthodontics, motivating practices to unlock their full potential, and ultimately supporting them in delivering better care to patients everywhere. About DentalMonitoring DentalMonitoring sets new standards in orthodontics with its AI-powered, FDA De Novo-approved, and MDR-certified remote monitoring software. Designed for use with multiple appliances or treatment phases, it enables doctors to monitor patients remotely, enhance clinical control, and improve efficiency. Patients benefit from features like in-app messaging, convenient guided scans, and real-time feedback. With its latest innovations, DentalMonitoring helps practices optimize workflows and deliver outstanding care. With over 13,000 clinical data results, DentalMonitoring is transforming the orthodontic experience for patients and practices worldwide by connecting innovation with orthodontic needs. View source version on Contacts Media Contact Celine Cendras-WhiteHead of Marketing North
